Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Gelion successfully transfers sulfur cathode material technology

(Sharecast News) - Gelion said on Wednesday that it has successfully transferred advanced sulfur cathode active material technology from the Max Planck Institute of Colloids and Interfaces into its own operations, marking a key milestone in the development of its next-generation lithium-sulfur and sodium-sulfur batteries. The AIM-traded battery innovator said fabrication of the material was now underway at its Sydney facility, giving it full in-house capability for production, prototyping and testing.

It said the move was expected to accelerate collaboration with partners by enabling larger-scale trials, faster feedback cycles and broader testing across multiple programmes, materially reducing technical risk and supporting the pathway to commercialisation.

"We are very pleased with the progress that has been achieved here working in collaboration with MPI," said chief executive John Wood.

"There has been exceptional commitment shown, including our research lead spending extended time at MPI to develop understanding and several individuals in our team going well above and beyond to allow for quick progress.

"Gelion is making progress with understanding and releasing the potential of this exceptional technology.

"The increased fabrication capability supports us continuing to step up our internal development activities along with our ability to support ongoing external testing activities."

Gelion said the expanded capacity would help advance its high-energy, high-power and long-life battery technologies towards market adoption.

At 1154 BST, Gelion shares were down 0.83% at 20.33p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.